Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 11/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508120 | 0.84 | KCNN4 (0.54) | KCNN4KCNE1KCNQ1KIF11EPHX1 | |
| SCHEMBL1508020 | 0.79 | KCNN4 (0.60) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL1507863 | 0.76 | KCNN4 (0.62) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL934496 | 0.76 | CYP2D6 (0.46) | KIF11EPHX1 | |
| SCHEMBL1507860 | 0.75 | KCNN4 (0.56) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL12834748 | 0.73 | KCNN4 (0.54) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL1508053 | 0.72 | KCNN4 (0.50) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL1508111 | 0.70 | KCNN4 (0.51) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL12834465 | 0.70 | KCNN4 (0.49) | KCNN4KCNE1KCNQ1KIF11NPC1 | |
| SCHEMBL1443968 | 0.70 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1KIF11NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | claimed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | claimed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | claimed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | claimed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | claimed |
| EP-2292595-A1 | Potassium channel modulators | NeuroSearch AS (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-7429618-B2 | Potassium channel modulators | NEUROSEARCH A/S (DK) | 2008-09-30 | — | — | US | disclosed |
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | disclosed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | disclosed |
| US-7208527-B2 | Potassium channel modulators | POSEIDON PHARMACEUTICALS A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | disclosed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009816-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885 |
| US-20070161607-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.